Media Centre

August 2018

From pharma to diagnostics: how Rhythm Biosciences found its new COO

Glenn Gilbert started out “literally pushing eggs around in a trolley” at biotech giant CSL in 2004 — and has risen through the ranks to become COO at bowel cancer tech startup Rhythm Biosciences.That was the same year Rhythm Biosciences (ASX:RHY) launched its flagship technology: inexpensive blood tests that can identify patients at high risk of having colon cancer. Read more

 

August 2018

Rhythm Biosciences thinks there’s a better way to find these cancer-causing polyps

New research suggests a type of colon polyp once considered rare may be more common than we think — potentially prompting a change in the way we test for colorectal cancer.Serrated polyposis syndrome, a condition that increases the risk of a patient developing colorectal (or bowel) cancer, was considered to occur in about 1 in every 3000 people. Read more

 

July 2018

Radiologists call for CTC bowel cancer scans, but a better option is close

Radiologists are calling on the government to add a new bowel cancer diagnostic tool to cut waiting times — but a better test may be just around the corner. The Royal Australian and New Zealand College of Radiologists (RANZCR) wants CT colonography (CTC) to be included in the Medicare Benefits Schedule in order to cut waiting times for colonoscopies. Read more

 

July 2018

Life Sciences Specialist Merchant Opportunities Fund ups stake in Rhythm Biosciences

Specialist life sciences fund Merchant Opportunities has upped its stake in medical diagnostics operation Rhythm Biosciences as the company continues to work on developing its simple colon cancer screening test.Merchant Opportunities fund has upped its stake in the company from 5.02 to 7.01 per cent acquiring an additional two million securities for $449,561. Read more

1 2 3 4